NICE-BAD clinical audit on psoriasis

Slides:

Advertisements

Similar presentations

Raptiva™ (efalizumab) Plaque Psoriasis: The Unmet Need

Advertisements

EUROPSO patient survey First top-line results September 19th 2002.

BADBIR BAD Biologic Interventions Register Dr Kathy McElhone 27 th June 2012.

(Date of presentation) (Name of presenter) UK IBD audit Biological therapies audit 2014 Comparison of (Your site name) results against the national results.

BAD Biologic Interventions Register (BADBIR ) An update November 2010.

British Association of Dermatologists’ Biologic Intervention Register (BADBIR) Update November 2007.

Rehabilitation Teaching and Research Unit, Wellington School of Medicine and Health Sciences Outcome measures in psoriatic arthritis Preliminary identification.

A pilot assessment of the impact and resource implications of a 48-hour ward-based stewardship team review on antibiotic use in a tertiary centre Nicola.

Gerald G Krueger MD Professor, Benning Presidential Endowed Chair

EXPRESS: Response Rates at Week Placebo (n=77) Infliximab 5 mg/kg (n=301) Per cent of patients Per cent of patients with.

BAD Biologic Interventions Register (BADBIR ) An update November 2009.

Follow-up on Abnormal Cancer Screenings: Creating a system-wide, EMR-based solution to improve patient safety and reduce medical errors Cambridge Health.

Phototherapy in Children Kathryn Thomson. Why are Children Different? Not just small adults –height –Body Surface Area:mass ratio –psychological differences:

Psoriasis Network in Arabic Countries Nejib DOSS Tunisia.

(Date of presentation) (Name of presenter) UK IBD audit Biological therapies audit 2014 Comparison of (Your site name) results against the national results.

Research Techniques Made Simple: Validation of Outcome Measures in Dermatology Kate V. Viola, MD, MHS 1 Tamar Nijsten, MD, PhD 2 Karthik Krishnamurthy,

1 Agenda  Overview –Burt Adelman MD  Efficacy and Pharmacodynamics –Akshay Vaishnaw MD, PhD  Safety –Gloria Vigliani MD  Alefacept Risk Benefit Profile.

GRAPPA Committee Reports and Outcome measures Dafna D. Gladman, MD, FRCPC Professor of Medicine, University of Toronto Director, PsA Program, University.

Number of phototherapy treatments for Psoriasis and Eczema: Audit of data collected at Whipps Cross over a three year period. Jane Watts Senior Nurse Melissa.

BAD clinical re-audit on isotretinoin Audit contributorsBAD members, with some contributions from non-members LeadsDavid de Berker, Tak Cheung and M Firouz.

Diagnosis and Management of Psoriasis and Psoriatic Arthritis

The pharmacist’s role: The rational use of topical steroids

Diagnosis and treatment algorithm for psoriasis

Fracture Liaison Service Database

Improving access through Innovation

Assessing Psoriasis in the Clinic: PGA and BSA

Difficult-to-Treat Psoriasis: Gaining Control of Palmoplantar and Nail Psoriasis.

Patients were considered not in MDA (MDA−) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA+) with a score of 5, 6 or 7 points.

Daniel Keith – Dermatology Registrar

Copyright © 2013 American Medical Association. All rights reserved.

Training on the Modular Approach on the assessment and management of psoriatic arthritis (PsA) for dermatology units This PsA Assessment initiative is.

British Association of Dermatologists National Clinical Audit Programme 2015: Atopic eczema in children (NICE CG57)

New Psoriasis Treatments

Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis Alan Menter,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Alexa B. Kimball,

Hospital Antibiotic Stewardship Programs

Psoriasis and Comorbidities Psoriasis and Cardiometabolic Comorbidities.

IL-17 Inhibitors in the Management of Psoriatic Disease

Efficacy of simvastatin in plaque psoriasis: A pilot study

Contemporary Issues in Psoriasis Care: A Call to Action

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

WORCESTERSHIRE PATHWAY for use of CYTOKINE MODULATORS in

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Narrowband-UVB treatment for psoriasis is highly economical and causes significant savings in cost for topical treatments K. Boswell,1 H. Cameron,1 J.

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

DRAFFT Impact Study - DIS

The Multifaceted Nature of Psoriasis Addressing Patients' Needs

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Ask the Psoriasis Expert

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Alan Menter, MD, Chair, Alice Gottlieb, MD, PhD, Steven R

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Can We Rely on the Dermatology Life Quality Index as a Measure of the Impact of Psoriasis or Atopic Dermatitis? James Twiss, David M. Meads, Elizabeth.

International Nutrition Survey 2011

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

BAD-BSDS-RCPath national audit on non-melanoma skin cancer excision

Epilepsy12 Patient Record Summary Dashboard

Alcohol Care Pathway As part of medical assessment, complete AUDIT-C

Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort Elaine Kunzler, MD, Stephanie Florez-Pollack,

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

When and How to Treat UTI Section 4: The Role of the Pharmacist

Jennifer L. Hundley, MD, Christie L

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

RCT pilot study comparing localised immersion PUVA with localised narrowband ultraviolet B (NBUVB) for treatment of palmar hand eczema D. Brass1, T.

Preventing Venous Thromboembolism Participating Hospital Survey

Women With Psoriasis Are Struggling More Than Men

Presentation transcript:

NICE-BAD clinical audit on psoriasis Audit contributors BAD members, with some contributions from non-members Leads David de Berker and Catherine Smith Audit standards source NICE clinical guidelines for the assessment and management of psoriasis 2012 (CG153) Completion date 3rd May 2013 Number of contributors 364 responses (4 unidentified) from 170 identifiable hospitals Number of patients 1092 total; 1080 when broken down by region Breakdown of the number of participants by region

Nursing and psychological support for psoriasis patients 2007 audit Nursing: 80.2% (n=100) Psychological: 41% (paed; n=93) 44% (adult; n=88) Percentage of responses for the availability of nursing and psychological support in 170 participating hospitals.

Prescription of systemic agents and BADBIR entry Percentage of responses for prescribing systemic agents and entry into BADBIR amongst 364 respondents.

Availability of phototherapy services (n=170) 2007 audit PUVA: 90% (n=96) UVB (TL01): 92% (n=97) Percentage of responses for the availability of PUVA and UVB services in 170 participating hospitals.

Phototherapy services waiting times Percentage of responses for the average waiting times for PUVA and UVB services in 167* participating hospitals. *Conflicting data for 3 hospitals currently still unresolved

Phototherapy services waiting times 2007 Percentage of responses for the average waiting times for PUVA and UVB services in 101 participating hospitals.

Physician’s Global Assessment Global results 72/84 13/18 107/123 103/129 53/63 79/102 37/57 35/42 101/129 90/114 41/60 48/66 38/60 20/33 (n = 1092) (n = 1080) Boxplots representing the distributional mean percentage of “Yes” responses to having recorded a PGA for each patient, per hospital in each region.

Psoriasis Area and Severity Index 12/18 60/129 31/60 Global results 49/66 52/63 45/84 73/102 80/129 40/57 62/123 29/42 71/114 31/60 10/33 (n = 1092) (n = 1080) Boxplots representing the distributional mean percentage of “Yes” responses to having recorded a PASI scoring for each patient, per hospital in each region.

Dermatology Life Quality Index 12/18 58/129 25/60 82/129 Global results 50/66 51/63 63/102 28/60 37/57 64/123 28/42 66/114 41/84 12/33 (n = 1092) (n = 1080) Boxplots representing the distributional mean percentage of “Yes” responses to having recorded a DLQI scoring for each patient, per hospital in each region.

Psoriasis Epidemiological Screening Tool 6/18 Global results 13/60 9/129 7/114 7/129 2/66 5/84 3/33 6/102 1/57 2/123 1/42 1/63 0/60 (n = 1092) (n = 1080) Boxplots representing the distributional mean percentage of “Yes” responses to having recorded a PEST scoring for each patient, per hospital in each region.

Psoriasis Epidemiological Screening Tool 6/13 8/96 7/60 13/46 7/81 1/28 3/19 6/66 2/34 5/43 2/72 1/30 1/49 0/28 (n = 667) Boxplots representing the distributional mean percentage of “Yes” responses to having recorded a PEST scoring for each of the 667 patients from identifiable hospitals who has been assessed for psoriatic arthritis, per hospital, in each region.

Involvement of nails, high-impact and difficult-to-treat sites 10/18 95/129 44/60 Global results 79/102 37/42 44/63 89/114 51/66 19/33 35/57 70/123 53/84 38/60 100/129 (n = 1092) (n = 1080) Boxplots representing the distributional mean percentage of “Yes” responses to having recorded involvement of nails, high-impact and difficult-to-treat sites in assessing disease severity for each patient, per hospital in each region.

Systemic upset Global results (n = 1092) (n = 1080) 33/114 21/66 6/33 Global results 5/18 42/129 9/57 13/84 15/123 6/42 4/60 28/129 21/60 24/63 39/102 (n = 1092) (n = 1080) Boxplots representing the distributional mean percentage of “Yes” responses to having recorded any systemic upset in assessing disease severity for each patient, per hospital in each region.

Assessment for psoriatic arthritis 13/18 28/60 81/129 30/42 Global results 74/123 46/60 49/63 96/129 28/57 60/114 34/66 43/84 19/33 66/102 (n = 1092) (n = 1080) Boxplots representing the distributional mean percentage of “Yes” responses to having recorded assessment for psoriatic arthritis for each patient, per hospital in each region.